Physician profile
Bolaji Sofola
NPI 1366406217
$10,612.24
in general payments reported to CMS, 2019-2025
47 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $1,129 · 2021: $1,233 · 2022: $1,398 · 2023: $2,645 · 2024: $1,395 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,636 · Travel and Lodging: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.23 |
| Travel and Lodging | $799.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,448.74 | 2019-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $1,378.24 | 2023-2025 | Aquabeam Robotic System |
| Bayer Healthcare Pharmaceuticals INC. | $795.26 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $735.74 | 2020-2025 | Prolaris, Myrisk |
| Medtronic, INC. | $635.40 | 2021-2025 | Interstim |
| Coloplast Corp | $528.46 | 2019-2025 | Altis |
| Sumitomo Pharma America, INC. | $524.84 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $497.74 | 2019-2025 | |
| Janssen Biotech, INC. | $401.79 | 2019-2023 | |
| Verity Pharmaceuticals INC. | $373.62 | 2022-2025 | Trelstar |
| Boston Scientific Corporation | $357.17 | 2019-2025 | Bulkamid, Axonics, Rezum Generator |
| Tolmar Pharmaceuticals, INC. | $296.60 | 2019-2022 | |
| Abbvie INC. | $247.67 | 2019-2025 | Lupron Depot |
| Endo Pharmaceuticals INC. | $219.32 | 2019-2024 | Xiaflex, Aveed |
| Teleflex LLC | $171.60 | 2021-2025 | Barrigel, Urolift |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $163.64 | 2021-2022 | |
| Neotract INC. | $162.04 | 2019-2020 | |
| Valencia Technologies Corporation | $157.71 | 2022-2024 | Ecoin Device Kit |
| Uromedica, Incorporated | $154.00 | 2020 | |
| Medtronic USA, INC. | $149.13 | 2019-2020 | |
| Urovant Sciences INC | $135.98 | 2021-2022 | |
| Tolmar, INC. | $121.83 | 2023-2025 | Jatenzo, Eligard |
| Healthtronics Stone Solutions, LLC | $109.51 | 2019 | |
| Olympus America INC. | $70.18 | 2022-2025 | Itind System |
| Kerecis Limited | $65.62 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bk Medical Holding Company INC. | $65.37 | 2023 | Bk3000, Bk3500 & Bk5000 Ultrasound System |
| Janssen Scientific Affairs, LLC | $63.52 | 2019 | |
| Endo USA, INC. | $53.83 | 2024-2025 | Xiaflex |
| Antares Pharma, INC. | $51.92 | 2020-2021 | |
| Lumenis, INC | $44.28 | 2021 | |
| Convatec INC. | $42.17 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $39.16 | 2023 | Lynparza |
| Progenics Pharmaceuticals, INC. | $37.29 | 2023-2024 | Pylarify |
| Laborie Medical Technologies Corp. | $37.26 | 2021 | |
| Caldera Medical, INC | $34.04 | 2022-2023 | Desara |
| Ferring Pharmaceuticals INC. | $33.60 | 2024-2025 | Adstiladrin |
| Axonics, INC. | $32.26 | 2020-2024 | Axonics |
| Immunitybio, INC. | $29.03 | 2025 | |
| Intuitive Surgical, INC. | $24.68 | 2019 | |
| Accord Healthcare, INC. | $20.90 | 2025 | |
| Blue Earth Diagnostics | $17.51 | 2019 | |
| Monaghan Medical Corporation | $16.25 | 2023 | Aerochamber |
| Urogen Pharma, INC. | $15.48 | 2023 | Jelmyto |
| Genzyme Corporation | $14.46 | 2020 | |
| Travere Therapeutics, INC. | $13.47 | 2020 | |
| Allergan, INC. | $11.97 | 2020 | |
| Cook Medical LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bolaji Sofola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.